Trade Organogenesis Holdings Inc. - ORGO CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 2.34
• Open: 2.4
• 1-Year Change: 19.4%
• Day's Range: 2.36 - 2.54

Organogenesis Holdings Inc. Company profile

About Organogenesis Holdings Inc

Organogenesis Holdings Inc. is a regenerative medicine company, which is focused on the development, manufacture, and commercialization of solutions for the wound care and surgical and sports medicine markets. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

Financial summary

BRIEF: For the nine months ended 30 September 2021,Organogenesis Holdings Inc revenues increased 47% to$339.5M. Net income totaled $43.2M vs. loss of $545K.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.01 to $0.34.